CoChat
Sign Up
Cited by 14

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Osteopontin in Cancer: Mechanisms and Therapeutic Targets

Kariya, Yoshinobu, Kariya, Yukiko·2022·International Journal of Translational Medicine
DOI 10.3390/ijtm2030033
Open this paper in CoChat — free account

Abstract

Despite significant advances in the understanding of cancer biology, cancer is still a leading cause of death worldwide. Expression of the tumor microenvironment component, osteopontin, in tumor tissues, plasma, and serum, has been shown to be associated with a poor prognosis and survival rate in various human cancers. Recent studies suggest that osteopontin drives tumor development and aggressiveness using various strategies. In this review, we first provide an overview of how osteopontin promotes tumor progression, such as tumor growth, invasion, angiogenesis, and immune modulation, as well as metastasis and chemoresistance. Next, we address how the functional activities of osteopontin are modulated by the interaction with integrins and CD44 receptors, but also by the post-translational modification, such as proteolytic processing by several proteases, phosphorylation, and glycosylation. Then, we review how osteopontin activates tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), and functions as an immunosuppressor by regulating immune surveillance and immune checkpoint in the tumor microenvironment. Finally, we discuss the potential applications of osteopontin as a biomarker and as a therapeutic target.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijtm2030033

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • OPN expression is increased after NFκB pathway activation.

    “OPN expression is increased after NFκB pathway activation 48”

    From Canonical Wnt pathway and the LDL receptor superfamily in neuronal cholesterol homeostasis and function (2024) · cites this paper as [48]

    Section 5, “OPN in Tumor Progression” (page unavailable), describes the opposite direction: OPN binding activates NF-κB signaling. Section 8 likewise places NF-κB signaling downstream of OPN induction, not as the trigger for increased OPN expression. (LLM, conf=0.86)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 228

  1. Sung, 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J. Clin., 71, 209, 10.3322/caac.21660 · DOI · Paper page
  2. Lee, 2021, Clinical Insights into Novel Immune Checkpoint Inhibitors, Front. Pharmacol., 12, 681320, 10.3389/fphar.2021.681320 · DOI
  3. Quail, 2013, Microenvironmental regulation of tumor progression and metastasis, Nat. Med., 19, 1423, 10.1038/nm.3394 · DOI · Paper page
  4. Wei, 2020, Cellular and Extracellular Components in Tumor Microenvironment and Their Application in Early Diagnosis of Cancers, Anal. Cell. Pathol., 2020, 6283796, 10.1155/2020/6283796 · DOI
  5. Senger, 1979, Transformed mammalian cells secrete specific proteins and phosphoproteins, Cell, 16, 885, 10.1016/0092-8674(79)90103-X · DOI
  6. Moorman, H.R., Poschel, D., Klement, J.D., Lu, C., Redd, P.S., and Liu, K. (2020). Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation. Cancers, 12. · DOI
  7. Pang, 2019, Osteopontin as a multifaceted driver of bone metastasis and drug resistance, Pharmacol. Res., 144, 235, 10.1016/j.phrs.2019.04.030 · DOI
  8. Kariya, 2014, Osteopontin O-glycosylation contributes to its phosphorylation and cell-adhesion properties, Biochem. J., 463, 93, 10.1042/BJ20140060 · DOI
  9. Kariya, Y., Oyama, M., Kariya, Y., and Hashimoto, Y. (2021). Phosphorylated Osteopontin Secreted from Cancer Cells Induces Cancer Cell Motility. Biomolecules, 11. · DOI
  10. Peraramelli, 2022, Thrombin cleavage of osteopontin initiates osteopontin’s tumor-promoting activity, J. Thromb. Haemost., 20, 1256, 10.1111/jth.15663 · DOI
  11. Chang, 2013, The O-glycosylation mutant osteopontin alters lung cancer cell growth and migration in vitro and in vivo, Int. J. Mol. Med., 32, 1137, 10.3892/ijmm.2013.1483 · DOI
  12. Kariya, 2018, β4-Integrin/PI3K Signaling Promotes Tumor Progression through the Galectin-3-N-Glycan Complex, Mol. Cancer Res., 16, 1024, 10.1158/1541-7786.MCR-17-0365 · DOI
  13. Schytte, 2020, FAM20C phosphorylation of the RGDSVVYGLR motif in osteopontin inhibits interaction with the αvβ3 integrin, J. Cell. Biochem., 121, 4809, 10.1002/jcb.29708 · DOI
  14. Shao, 2017, MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells, Biochem. Biophys. Res. Commun., 493, 1478, 10.1016/j.bbrc.2017.10.009 · DOI
  15. Virchow, R. (1863). Cellular Pathology as Based upon Physiological and Pathological Histology, J. B. Lippincott. · DOI
  16. Gerarduzzi, 2020, The Matrix Revolution: Matricellular Proteins and Restructuring of the Cancer Microenvironment, Cancer Res., 80, 2705, 10.1158/0008-5472.CAN-18-2098 · DOI
  17. Lamort, A.S., Giopanou, I., Psallidas, I., and Stathopoulos, G.T. (2019). Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight. Cells, 8. · DOI
  18. Rosmus, D.-D., Lange, C., Ludwig, F., Ajami, B., and Wieghofer, P. (2022). The Role of Osteopontin in Microglia Biology: Current Concepts and Future Perspectives. Biomedicines, 10. · DOI
  19. Singh, 2018, Role of osteopontin in bone remodeling and orthodontic tooth movement: A review, Prog. Orthod., 19, 18, 10.1186/s40510-018-0216-2 · DOI
  20. Kariya, 2015, Increased cerebrospinal fluid osteopontin levels and its involvement in macrophage infiltration in neuromyelitis optica, BBA Clin., 3, 126, 10.1016/j.bbacli.2015.01.003 · DOI
  21. Demmelmair, H., Prell, C., Timby, N., and Lönnerdal, B. (2017). Benefits of Lactoferrin, Osteopontin and Milk Fat Globule Membranes for Infants. Nutrients, 9. · DOI
  22. Yang, 2012, Osteopontin and integrin are involved in cholesterol gallstone formation, Med. Sci. Monit. Int. Med. J. Exp. Clin. Res., 18, BR16
  23. Kahles, 2014, Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes, Mol. Metab., 3, 384, 10.1016/j.molmet.2014.03.004 · DOI
  24. Sodek, 2000, Osteopontin. Critical reviews in oral biology and medicine: An official publication of the American Association of Oral Biologists, Crit. Rev. Oral Biol. Med., 11, 279, 10.1177/10454411000110030101 · DOI
  25. Kazanecki, 2007, Control of osteopontin signaling and function by post-translational phosphorylation and protein folding, J. Cell. Biochem., 102, 912, 10.1002/jcb.21558 · DOI
  26. Yim, A., Smith, C., and Brown, A.M. (2022). Osteopontin/secreted phosphoprotein-1 harnesses glial-, immune-, and neuronal cell ligand-receptor interactions to sense and regulate acute and chronic neuroinflammation. Immunol. Rev., early view. · DOI
  27. Song, 2021, Osteopontin Takes Center Stage in Chronic Liver Disease, Hepatology, 73, 1594, 10.1002/hep.31582 · DOI
  28. Anan, G., Yoneyama, T., Noro, D., Tobisawa, Y., Hatakeyama, S., Sutoh Yoneyama, M., Yamamoto, H., Imai, A., Iwamura, H., and Kohada, Y. (2020). The Impact of Glycosylation of Osteopontin on Urinary Stone Formation. Int. J. Mol. Sci., 21. · DOI
  29. Wright, 2015, Intrinsically disordered proteins in cellular signalling and regulation, Nat. Rev. Mol. Cell Biol., 16, 18, 10.1038/nrm3920 · DOI
  30. Martinelli, A., Lopes, F., John, E., Carlini, C., and Ligabue-Braun, R. (2019). Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies. Int. J. Mol. Sci., 20. · DOI
  31. Gimba, 2019, Full-length osteopontin and its splice variants as modulators of chemoresistance and radioresistance (Review), Int. J. Oncol., 54, 420
  32. Katagiri, 1999, CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis, Cancer Res., 59, 219
  33. Kanayama, 2017, Skewing of the population balance of lymphoid and myeloid cells by secreted and intracellular osteopontin, Nat. Immunol., 18, 973, 10.1038/ni.3791 · DOI
  34. Liu, 2022, A pan-cancer analysis of the oncogenic role of secreted phosphoprotein 1 (SPP1) in human cancers, Ann. Transl. Med., 10, 279, 10.21037/atm-22-829 · DOI
  35. Subraman, 2015, OPN—Revisited, J. Clin. Diagn. Res., 9, ZE10
  36. Hao, 2017, Human osteopontin: Potential clinical applications in cancer (Review), Int. J. Mol. Med., 39, 1327, 10.3892/ijmm.2017.2964 · DOI
  37. Chen, 2019, Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma, Cancer Cell, 35, 868, 10.1016/j.ccell.2019.05.003 · DOI
  38. Zhang, 2020, Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer, Cell, 181, 442, 10.1016/j.cell.2020.03.048 · DOI
  39. Yonemitsu, 2021, Soluble Factors Involved in Cancer Cell-Macrophage Interaction Promote Breast Cancer Growth, Anticancer Res., 41, 4249, 10.21873/anticanres.15229 · DOI
  40. Nagel, 2022, Alpha-smooth muscle actin-positive cancer-associated fibroblasts secreting osteopontin promote growth of luminal breast cancer, Cell. Mol. Biol. Lett., 27, 45, 10.1186/s11658-022-00351-7 · DOI
  41. Shiomi, 2021, Comprehensive genomic analysis contrasting primary colorectal cancer and matched liver metastases, Oncol. Lett., 21, 466, 10.3892/ol.2021.12727 · DOI
  42. Coombes, 2017, Osteopontin splice variants and polymorphisms in cancer progression and prognosis, Biochim. Biophys. Acta BBA Rev. Cancer, 1868, 93, 10.1016/j.bbcan.2017.02.005 · DOI
  43. Adams, 2019, Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer, eLife, 8, e45313, 10.7554/eLife.45313 · DOI
  44. Feng, Y.-H., Su, Y.-C., Lin, S.-F., Lin, P.-R., Wu, C.-L., Tung, C.-L., Li, C.-F., Shieh, G.-S., and Shiau, A.-L. (2019). Oct4 upregulates osteopontin via Egr1 and is associated with poor outcome in human lung cancer. BMC Cancer, 19. · DOI
  45. Krstic, 2020, Isoform-specific promotion of breast cancer tumorigenicity by TBX3 involves induction of angiogenesis, Lab. Investig., 100, 400, 10.1038/s41374-019-0326-6 · DOI
  46. Liu, 2021, RUNX1 promotes MAPK signaling to increase tumor progression and metastasis via OPN in head and neck cancer, Carcinogenesis, 42, 414, 10.1093/carcin/bgaa116 · DOI
  47. Deiana, M., Dalle Carbonare, L., Serena, M., Cheri, S., Mutascio, S., Gandini, A., Innamorati, G., Lorenzi, P., Cumerlato, M., and Bertacco, J. (2020). A Potential Role of RUNX2- RUNT Domain in Modulating the Expression of Genes Involved in Bone Metastases: An In Vitro Study with Melanoma Cells. Cells, 9. · DOI
  48. Whittle, 2015, RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma, Cell, 161, 1345, 10.1016/j.cell.2015.04.048 · DOI
  49. Amilca-Seba, K., Tan, T.Z., Thiery, J.-P., Louadj, L., Thouroude, S., Bouygues, A., Sabbah, M., Larsen, A.K., and Denis, J.A. (2022). Osteopontin (OPN/SPP1), a Mediator of Tumor Progression, Is Regulated by the Mesenchymal Transcription Factor Slug/SNAI2 in Colorectal Cancer (CRC). Cells, 11. · DOI
  50. Thomann, 2020, YAP Orchestrates Heterotypic Endothelial Cell Communication via HGF/c-MET Signaling in Liver Tumorigenesis, Cancer Res., 80, 5502, 10.1158/0008-5472.CAN-20-0242 · DOI
  51. Klement, 2018, An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion, J. Clin. Investig., 128, 5549, 10.1172/JCI123360 · DOI
  52. Sun, 2021, Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3, Signal Transduct. Target. Ther., 6, 187, 10.1038/s41392-021-00579-3 · DOI
  53. Li, 2021, ADAM8 affects glioblastoma progression by regulating osteopontin-mediated angiogenesis, Biol. Chem., 402, 195, 10.1515/hsz-2020-0184 · DOI
  54. Gan, 2017, Osteopontin is Critical for Hyperactive mTOR-Induced Tumorigenesis in Oral Squamous Cell Carcinoma, J. Cancer, 8, 1362, 10.7150/jca.18031 · DOI
  55. Schulz, 2020, Linking NRP2 With EMT and Chemoradioresistance in Bladder Cancer, Front. Oncol., 9, 1461, 10.3389/fonc.2019.01461 · DOI
  56. Yang, 2020, Squalene synthase promotes the invasion of lung cancer cells via the osteopontin/ERK pathway, Oncogenesis, 9, 78, 10.1038/s41389-020-00262-2 · DOI
  57. Curtis, 2020, Mechanical stimuli and matrix properties modulate cancer spheroid growth in three-dimensional gelatin culture, J. R. Soc. Interface, 17, 20200568, 10.1098/rsif.2020.0568 · DOI
  58. Kolb, 2005, Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions, Cancer Biol. Ther., 4, 740, 10.4161/cbt.4.7.1821 · DOI
  59. Chang, 2019, Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin, FASEB J., 33, 114, 10.1096/fj.201800019RR · DOI
  60. Wang, S.-Y., Chen, C.-L., Hu, Y.-C., Chi, Y., Huang, Y.-H., Su, C.-W., Jeng, W.-J., Liang, Y.-J., and Wu, J.-C. (2019). High Expression of MicroRNA-196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients. Cancers, 11. · DOI
  61. Marisetty, A., Wei, J., Kong, L.-Y., Ott, M., Fang, D., Sabbagh, A., and Heimberger, A.B. (2020). MiR-181 Family Modulates Osteopontin in Glioblastoma Multiforme. Cancers, 12. · DOI
  62. Farina, 2016, Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells, Oncotarget, 7, 79032, 10.18632/oncotarget.12593 · DOI
  63. Colden, 2017, MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2, Cell Death Dis., 8, e2572, 10.1038/cddis.2017.15 · DOI
  64. Qiu, 2022, Metformin suppresses lung adenocarcinoma by downregulating long non-coding RNA (lncRNA) AFAP1-AS1 and secreted phosphoprotein 1 (SPP1) while upregulating miR-3163, Bioengineered, 13, 11987, 10.1080/21655979.2021.2005981 · DOI
  65. Amilca-Seba, K., Sabbah, M., Larsen, A.K., and Denis, J.A. (2021). Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications. Cancers, 13. · DOI
  66. Lu, 2021, WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape, J. Immunother. Cancer, 9, e002624, 10.1136/jitc-2021-002624 · DOI
  67. Giopanou, 2020, Osteopontin drives KRAS-mutant lung adenocarcinoma, Carcinogenesis, 41, 1134, 10.1093/carcin/bgz190 · DOI
  68. Wu, 2022, Osteopontin promotes hepatocellular carcinoma progression through inducing JAK2/STAT3/NOX1-mediated ROS production, Cell Death Dis., 13, 341, 10.1038/s41419-022-04806-9 · DOI
  69. Cao, 2019, Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial–mesenchymal transition and cancer stem cell-like properties by modulating forkhead box protein M1, Mol. Oncol., 13, 228, 10.1002/1878-0261.12399 · DOI
  70. Luo, 2011, Osteopontin Stimulates Preneoplastic Cellular Proliferation Through Activation of the MAPK Pathway, Mol. Cancer Res., 9, 1018, 10.1158/1541-7786.MCR-10-0472 · DOI
  71. Qian, 2021, Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling, J. Clin. Investig., 131, e146186, 10.1172/JCI146186 · DOI
  72. Cao, 2015, Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway, Oncotarget, 6, 6627, 10.18632/oncotarget.3113 · DOI
  73. Rao, 2013, Reciprocal Interactions between Tumor-Associated Macrophages and CD44-Positive Cancer Cells via Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer, Clin. Cancer Res., 19, 785, 10.1158/1078-0432.CCR-12-2788 · DOI
  74. Huang, 2017, Osteopontin Promotes Cell Migration and Invasion, and Inhibits Apoptosis and Autophagy in Colorectal Cancer by activating the p38 MAPK Signaling Pathway, Cell. Physiol. Biochem., 41, 1851, 10.1159/000471933 · DOI
  75. Ahmed, 2016, An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression, Cancer Cell, 30, 432, 10.1016/j.ccell.2016.08.002 · DOI
  76. Gupta, 2013, Osteopontin and MMP9: Associations with VEGF Expression/Secretion and Angiogenesis in PC3 Prostate Cancer Cells, Cancers, 5, 617, 10.3390/cancers5020617 · DOI
  77. Pitarresi, 2021, PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability, Cancer Discov., 11, 1774, 10.1158/2159-8290.CD-20-1098 · DOI
  78. Liu, 2019, Secreted Phosphoprotein 1 Promotes the Development of Small Cell Lung Cancer Cells by Inhibiting Autophagy and Apoptosis, Pathol. Oncol. Res., 25, 1487, 10.1007/s12253-018-0504-7 · DOI
  79. Napoli, S., Scuderi, C., Gattuso, G., Di Bella, V., Candido, S., Basile, M.S., Libra, M., and Falzone, L. (2020). Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma. Cells, 9. · DOI
  80. Chen, 2011, Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA, Oncol. Rep., 25, 803
  81. Kechagia, 2019, Integrins as biomechanical sensors of the microenvironment, Nat. Rev. Mol. Cell Biol., 20, 457, 10.1038/s41580-019-0134-2 · DOI · Paper page
  82. Kariya, Y., Kariya, Y., and Gu, J. (2017). Roles of Integrin α6β4 Glycosylation in Cancer. Cancers, 9. · DOI
  83. Cooper, 2019, Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance, Cancer Cell, 35, 347, 10.1016/j.ccell.2019.01.007 · DOI
  84. Ludwig, B.S., Kessler, H., Kossatz, S., and Reuning, U. (2021). RGD-Binding Integrins Revisited: How Recently Discovered Functions and Novel Synthetic Ligands (Re-)Shape an Ever-Evolving Field. Cancers, 13. · DOI
  85. Desgrosellier, 2010, Integrins in cancer: Biological implications and therapeutic opportunities, Nat. Rev. Cancer, 10, 9, 10.1038/nrc2748 · DOI
  86. Vogetseder, 2013, αv-Integrin isoform expression in primary human tumors and brain metastases, Int. J. Cancer, 133, 2362, 10.1002/ijc.28267 · DOI
  87. Avraamides, 2008, Integrins in angiogenesis and lymphangiogenesis, Nat. Rev. Cancer, 8, 604, 10.1038/nrc2353 · DOI · Paper page
  88. Warneke, 2015, Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancer, Gastric Cancer, 18, 784, 10.1007/s10120-014-0435-2 · DOI
  89. Baiula, 2019, Novel Ligands Targeting α4β1 Integrin: Therapeutic Applications and Perspectives, Front. Chem., 7, 489, 10.3389/fchem.2019.00489 · DOI
  90. LaFoya, B., Munroe, J.A., Miyamoto, A., Detweiler, M.A., Crow, J.J., Gazdik, T., and Albig, A.R. (2018). Beyond the Matrix: The Many Non-ECM Ligands for Integrins. Int. J. Mol. Sci., 19. · DOI
  91. Taooka, 1999, The integrin alpha9beta1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-1, J. Cell Biol., 145, 413, 10.1083/jcb.145.2.413 · DOI
  92. Kale, 2014, Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin, Oncogene, 33, 2295, 10.1038/onc.2013.184 · DOI
  93. Krishn, 2020, The αvβ6 integrin in cancer cell-derived small extracellular vesicles enhances angiogenesis, J. Extracell. Vesicles, 9, 1763594, 10.1080/20013078.2020.1763594 · DOI
  94. Oyama, 2018, Biological role of site-specific O-glycosylation in cell adhesion activity and phosphorylation of osteopontin, Biochem. J., 475, 1583, 10.1042/BCJ20170205 · DOI
  95. Fan, 2018, Osteopontin-integrin engagement induces HIF-1α-TCF12-mediated endothelial-mesenchymal transition to exacerbate colorectal cancer, Oncotarget, 9, 4998, 10.18632/oncotarget.23578 · DOI
  96. Hsieh, 2013, Upregulation of drug transporter expression by osteopontin in prostate cancer cells, Mol. Pharmacol., 83, 968, 10.1124/mol.112.082339 · DOI
  97. Lu, 2020, Integrated analysis reveals critical glycolytic regulators in hepatocellular carcinoma, Cell Commun. Signal., 18, 97, 10.1186/s12964-020-00539-4 · DOI
  98. Che, P., Yu, L., Friedman, G.K., Wang, M., Ke, X., Wang, H., Zhang, W., Nabors, B., Ding, Q., and Han, X. (2021). Integrin αvβ3 Engagement Regulates Glucose Metabolism and Migration through Focal Adhesion Kinase (FAK) and Protein Arginine Methyltransferase 5 (PRMT5) in Glioblastoma Cells. Cancers, 13. · DOI
  99. Park, J.H., Pyun, W.Y., and Park, H.W. (2020). Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets. Cells, 9. · DOI
  100. Shi, Z., Wang, B., Chihanga, T., Kennedy, M.A., and Weber, G.F. (2014). Energy Metabolism during Anchorage-Independence. Induction by Osteopontin-c. PLoS ONE, 9. · DOI
  101. Senbanjo, 2017, CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells, Front. Cell Dev. Biol., 5, 18, 10.3389/fcell.2017.00018 · DOI
  102. Hassn Mesrati, M., Syafruddin, S.E., Mohtar, M.A., and Syahir, A. (2021). CD44: A Multifunctional Mediator of Cancer Progression. Biomolecules, 11. · DOI
  103. Fnu, G., Agrawal, P., Kundu, G.C., and Weber, G.F. (2021). Structural Constraint of Osteopontin Facilitates Efficient Binding to CD44. Biomolecules, 11. · DOI
  104. Weber, 1996, Receptor-ligand interaction between CD44 and osteopontin (Eta-1), Science, 271, 509, 10.1126/science.271.5248.509 · DOI
  105. Yan, 2015, Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target, Stem Cells Transl. Med., 4, 1033, 10.5966/sctm.2015-0048 · DOI
  106. Nallasamy, 2021, Pancreatic Tumor Microenvironment Factor Promotes Cancer Stemness via SPP1–CD44 Axis, Gastroenterology, 161, 1998, 10.1053/j.gastro.2021.08.023 · DOI
  107. Pietras, 2014, Osteopontin-CD44 Signaling in the Glioma Perivascular Niche Enhances Cancer Stem Cell Phenotypes and Promotes Aggressive Tumor Growth, Cell Stem Cell, 14, 357, 10.1016/j.stem.2014.01.005 · DOI
  108. Viana, B.P.P.B., Gomes, A.V.P., Gimba, E.R.P., and Ferreira, L.B. (2021). Osteopontin Expression in Thyroid Cancer: Deciphering EMT-Related Molecular Mechanisms. Biomedicines, 9. · DOI
  109. Kothari, A., Arffa, M., Chang, V., Blackwell, R., Syn, W.-K., Zhang, J., Mi, Z., and Kuo, P. (2016). Osteopontin—A Master Regulator of Epithelial-Mesenchymal Transition. J. Clin. Med., 5. · DOI
  110. Aiello, 2019, Context-dependent EMT programs in cancer metastasis, J. Exp. Med., 216, 1016, 10.1084/jem.20181827 · DOI
  111. Bakir, 2020, EMT, MET, Plasticity, and Tumor Metastasis, Trends Cell Biol., 30, 764, 10.1016/j.tcb.2020.07.003 · DOI
  112. Shi, 2021, Regulatory roles of osteopontin in human lung cancer cell epithelial-to-mesenchymal transitions and responses, Clin. Transl. Med., 11, e486, 10.1002/ctm2.486 · DOI
  113. Hao, 2019, OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase, Sci. Rep., 9, 18101, 10.1038/s41598-019-54843-2 · DOI
  114. Jia, 2016, Osteopontin facilitates tumor metastasis by regulating epithelial–mesenchymal plasticity, Cell Death Dis., 7, e2564, 10.1038/cddis.2016.422 · DOI
  115. Saitoh, 2018, Involvement of partial EMT in cancer progression, J. Biochem., 164, 257, 10.1093/jb/mvy047 · DOI
  116. Kariya, 2021, αvβ3 Integrin induces partial EMT independent of TGF-β signaling, Commun. Biol., 4, 490, 10.1038/s42003-021-02003-6 · DOI
  117. Ding, 2015, Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC, Oncol. Rep., 34, 3297, 10.3892/or.2015.4306 · DOI
  118. Ng, 2015, Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer, Stem Cells Int., 2015, 247892, 10.1155/2015/247892 · DOI
  119. Qian, 2015, Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl-2 pathway, Mol. Med. Rep., 11, 1951, 10.3892/mmr.2014.2951 · DOI
  120. Pein, 2018, Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis, EMBO Mol. Med., 10, e9003, 10.15252/emmm.201809003 · DOI
  121. Yang, 2015, Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine, Mol. Cancer, 14, 179, 10.1186/s12943-015-0449-3 · DOI
  122. Liu, 2016, Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells, Cancer Lett., 383, 171, 10.1016/j.canlet.2016.09.033 · DOI
  123. Fu, 2020, Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer, J. Hematol. Oncol., 13, 169, 10.1186/s13045-020-01009-7 · DOI
  124. Zhang, 2020, Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer, Transl. Cancer Res., 9, 754, 10.21037/tcr.2019.12.49 · DOI
  125. Wang, 2019, Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer, Oncol. Res. Featur. Preclin. Clin. Cancer Ther., 27, 871
  126. Mansoori, 2017, The Different Mechanisms of Cancer Drug Resistance: A Brief Review, Adv. Pharm. Bull., 7, 339, 10.15171/apb.2017.041 · DOI
  127. Graessmann, 2007, Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3, Oncogene, 26, 2840, 10.1038/sj.onc.1210096 · DOI
  128. Horala, A., Swiatly, A., Matysiak, J., Banach, P., Nowak-Markwitz, E., and Kokot, Z. (2017). Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay. Int. J. Mol. Sci., 18. · DOI
  129. Chakraborty, 2008, Osteopontin Promotes Vascular Endothelial Growth Factor–Dependent Breast Tumor Growth and Angiogenesis via Autocrine and Paracrine Mechanisms, Cancer Res., 68, 152, 10.1158/0008-5472.CAN-07-2126 · DOI
  130. Dai, 2009, Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells, Oncogene, 28, 3412, 10.1038/onc.2009.189 · DOI
  131. Raja, 2014, Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis, Oncogene, 33, 2053, 10.1038/onc.2013.171 · DOI
  132. Jain, 2006, The Crucial Role of Cyclooxygenase-2 in Osteopontin-Induced Protein Kinase C α/c-Src/IκB Kinase α/β–Dependent Prostate Tumor Progression and Angiogenesis, Cancer Res., 66, 6638, 10.1158/0008-5472.CAN-06-0661 · DOI
  133. Łukaszewicz-Zając, M., Pączek, S., and Mroczko, B. (2022). A Disintegrin and Metalloproteinase (ADAM) Family—Novel Biomarkers of Selected Gastrointestinal (GI) Malignancies?. Cancers, 14. · DOI
  134. Kobori, 2018, Interleukin-18 Amplifies Macrophage Polarization and Morphological Alteration, Leading to Excessive Angiogenesis, Front. Immunol., 9, 334, 10.3389/fimmu.2018.00334 · DOI
  135. Nakagami, 2020, Cellular senescence and senescence-associated T cells as a potential therapeutic target, Geriatr. Gerontol. Int., 20, 97, 10.1111/ggi.13851 · DOI
  136. Ohtani, 2022, The roles and mechanisms of senescence-associated secretory phenotype (SASP): Can it be controlled by senolysis?, Inflamm. Regen., 42, 11, 10.1186/s41232-022-00197-8 · DOI
  137. Flanagan, 2018, c-Myb and C/EBPβ regulate OPN and other senescence-associated secretory phenotype factors, Oncotarget, 9, 21, 10.18632/oncotarget.22940 · DOI
  138. Liu, 2012, Tiam1-regulated osteopontin in senescent fibroblasts contributes to the migration and invasion of associated epithelial cells, J. Cell Sci., 125, 376, 10.1242/jcs.089466 · DOI
  139. Xu, 2016, The fibroblast Tiam1-osteopontin pathway modulates breast cancer invasion and metastasis, Breast Cancer Res., 18, 14, 10.1186/s13058-016-0674-8 · DOI
  140. Kyjacova, 2021, IER2-induced senescence drives melanoma invasion through osteopontin, Oncogene, 40, 6494, 10.1038/s41388-021-02027-6 · DOI
  141. Zuo, 2021, Fam20C Regulates Bone Resorption and Breast Cancer Bone Metastasis through Osteopontin and BMP4, Cancer Res., 81, 5242, 10.1158/0008-5472.CAN-20-3328 · DOI
  142. Kovacheva, M., Zepp, M., Schraad, M., Berger, S., and Berger, M.R. (2019). Conditional Knockdown of Osteopontin Inhibits Breast Cancer Skeletal Metastasis. Int. J. Mol. Sci., 20. · DOI
  143. Zhao, 2007, Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases, Cancer Res., 67, 5821, 10.1158/0008-5472.CAN-06-4499 · DOI
  144. Terpos, 2009, The clinical significance of serum markers of bone turnover in NSCLC patients: Surveillance, management and prognostic implications, Anticancer Res., 29, 1651
  145. Chang, 2017, Parathyroid Hormone-Like Hormone is a Poor Prognosis Marker of Head and Neck Cancer and Promotes Cell Growth via RUNX2 Regulation, Sci. Rep., 7, 41131, 10.1038/srep41131 · DOI
  146. Edwards, 2021, From Good to Bad: The Opposing Effects of PTHrP on Tumor Growth, Dormancy, and Metastasis Throughout Cancer Progression, Front. Oncol., 11, 644303, 10.3389/fonc.2021.644303 · DOI
  147. Pinho, 2015, Glycosylation in cancer: Mechanisms and clinical implications, Nat. Rev. Cancer, 15, 540, 10.1038/nrc3982 · DOI
  148. Mereiter, 2019, Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?, Cancer Cell, 36, 6, 10.1016/j.ccell.2019.06.006 · DOI
  149. Darling, 2018, Intrinsic Disorder and Posttranslational Modifications: The Darker Side of the Biological Dark Matter, Front. Genet., 9, 158, 10.3389/fgene.2018.00158 · DOI
  150. Dean, 2007, Proteomics Discovery of Metalloproteinase Substrates in the Cellular Context by iTRAQ™ Labeling Reveals a Diverse MMP-2 Substrate Degradome, Mol. Cell. Proteom., 6, 611, 10.1074/mcp.M600341-MCP200 · DOI
  151. Agnihotri, 2001, Osteopontin, a Novel Substrate for Matrix Metalloproteinase-3 (Stromelysin-1) and Matrix Metalloproteinase-7 (Matrilysin), J. Biol. Chem., 276, 28261, 10.1074/jbc.M103608200 · DOI
  152. Yamaguchi, 2013, Thrombin-cleaved Fragments of Osteopontin Are Overexpressed in Malignant Glial Tumors and Provide a Molecular Niche with Survival Advantage, J. Biol. Chem., 288, 3097, 10.1074/jbc.M112.362954 · DOI
  153. Takafuji, 2007, An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma, Oncogene, 26, 6361, 10.1038/sj.onc.1210463 · DOI
  154. Mi, 2007, Thrombin-Cleaved COOH-Terminal Osteopontin Peptide Binds with Cyclophilin C to CD147 in Murine Breast Cancer Cells, Cancer Res., 67, 4088, 10.1158/0008-5472.CAN-06-4066 · DOI
  155. Yokosaki, 1999, The Integrin α9β1 Binds to a Novel Recognition Sequence (SVVYGLR) in the Thrombin-cleaved Amino-terminal Fragment of Osteopontin, J. Biol. Chem., 274, 36328, 10.1074/jbc.274.51.36328 · DOI
  156. Senger, 1994, Adhesive properties of osteopontin: Regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain, Mol. Biol. Cell, 5, 565, 10.1091/mbc.5.5.565 · DOI
  157. Yokosaki, 2005, Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin, Matrix Biol. J. Int. Soc. Matrix Biol., 24, 418, 10.1016/j.matbio.2005.05.005 · DOI
  158. Malaponte, 2016, Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression, Biochim. Biophys. Acta, 1863, 483, 10.1016/j.bbamcr.2015.09.018 · DOI
  159. Lee, 2016, Protein Regulation in Signal Transduction, Cold Spring Harb. Perspect. Biol., 8, a005918, 10.1101/cshperspect.a005918 · DOI
  160. Mateos, 2021, Hyperphosphorylation of Human Osteopontin and Its Impact on Structural Dynamics and Molecular Recognition, Biochemistry, 60, 1347, 10.1021/acs.biochem.1c00050 · DOI
  161. Yalak, 2012, Extracellular phosphorylation and phosphorylated proteins: Not just curiosities but physiologically important, Sci. Signal., 5, re7, 10.1126/scisignal.2003273 · DOI
  162. Yamaguchi, 2010, NMR characterization of intramolecular interaction of osteopontin, an intrinsically disordered protein with cryptic integrin-binding motifs, Biochem. Biophys. Res. Commun., 393, 487, 10.1016/j.bbrc.2010.02.030 · DOI
  163. Weber, 2002, Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation, J. Leukoc. Biol., 72, 752, 10.1189/jlb.72.4.752 · DOI
  164. Zhang, H., Cai, Y.-H., Ding, Y., Zhang, G., Liu, Y., Sun, J., Yang, Y., Zhan, Z., Iliuk, A., and Gu, Z. (2022). Proteomics, Phosphoproteomics and Mirna Analysis of Circulating Extracellular Vesicles through Automated and High-Throughput Isolation. Cells, 11. · DOI
  165. Tagliabracci, 2015, A Single Kinase Generates the Majority of the Secreted Phosphoproteome, Cell, 161, 1619, 10.1016/j.cell.2015.05.028 · DOI
  166. Liu, 2021, Prognostic and immunological role of Fam20C in pan-cancer, Biosci. Rep., 41, BSR20201920, 10.1042/BSR20201920 · DOI
  167. Stowell, 2015, Protein Glycosylation in Cancer, Annu. Rev. Pathol. Mech. Dis., 10, 473, 10.1146/annurev-pathol-012414-040438 · DOI · Paper page
  168. Kariya, 2020, Quantitative analysis of β1,6GlcNAc-branched N-glycans on β4 integrin in cutaneous squamous cell carcinoma, Fukushima J. Med. Sci., 66, 119, 10.5387/fms.2020-12 · DOI
  169. Masuda, 2000, N-Glycan structures of an osteopontin from human bone, Biochem. Biophys. Res. Commun., 268, 814, 10.1006/bbrc.2000.2224 · DOI
  170. Shanmugam, 1997, Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells, Biochemistry, 36, 5729, 10.1021/bi961687w · DOI
  171. Patarca, 1989, Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection, J. Exp. Med., 170, 145, 10.1084/jem.170.1.145 · DOI
  172. Klement, J.D., Poschel, D.B., Lu, C., Merting, A.D., Yang, D., Redd, P.S., and Liu, K. (2021). Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression. Cancers, 13. · DOI
  173. Wei, 2019, Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target, J. Clin. Investig., 129, 137, 10.1172/JCI121266 · DOI
  174. Zhu, 2019, Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade, Gut, 68, 1653, 10.1136/gutjnl-2019-318419 · DOI · Paper page
  175. Wisniewski, 2016, Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression, Oncogene, 35, 6366, 10.1038/onc.2016.55 · DOI
  176. Sangaletti, 2014, Osteopontin Shapes Immunosuppression in the Metastatic Niche, Cancer Res., 74, 4706, 10.1158/0008-5472.CAN-13-3334 · DOI
  177. Kim, 2014, Tumor-Derived Osteopontin Suppresses Antitumor Immunity by Promoting Extramedullary Myelopoiesis, Cancer Res., 74, 6705, 10.1158/0008-5472.CAN-14-1482 · DOI
  178. Lin, 2019, Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications, J. Hematol. Oncol., 12, 76, 10.1186/s13045-019-0760-3 · DOI · Paper page
  179. DeNardo, 2019, Macrophages as regulators of tumour immunity and immunotherapy, Nat. Rev. Immunol., 19, 369, 10.1038/s41577-019-0127-6 · DOI
  180. Li, 2021, Multi-Omics Analysis Showed the Clinical Value of Gene Signatures of C1QC+ and SPP1+ TAMs in Cervical Cancer, Front. Immunol., 12, 694801, 10.3389/fimmu.2021.694801 · DOI
  181. Qi, 2022, Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer, Nat. Commun., 13, 1742, 10.1038/s41467-022-29366-6 · DOI
  182. Castello, 2017, Osteopontin at the Crossroads of Inflammation and Tumor Progression, Mediat. Inflamm., 2017, 4049098, 10.1155/2017/4049098 · DOI
  183. Wykes, 2018, Immune checkpoint blockade in infectious diseases, Nat. Rev. Immunol., 18, 91, 10.1038/nri.2017.112 · DOI
  184. Li, 2021, Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC), Thorac. Cancer, 12, 2698, 10.1111/1759-7714.14108 · DOI
  185. Raineri, 2020, Osteopontin binds ICOSL promoting tumor metastasis, Commun. Biol., 3, 615, 10.1038/s42003-020-01333-1 · DOI
  186. Raineri, D., Cappellano, G., Vilardo, B., Maione, F., Clemente, N., Canciani, E., Boggio, E., Gigliotti, C.L., Monge, C., and Dianzani, C. (2021). Inducible T-Cell Costimulator Ligand Plays a Dual Role in Melanoma Metastasis upon Binding to Osteopontin or Inducible T-Cell Costimulator. Biomedicines, 10. · DOI
  187. Louault, K., Li, R.-R., and DeClerck, Y.A. (2020). Cancer-Associated Fibroblasts: Understanding Their Heterogeneity. Cancers, 12. · DOI
  188. Mi, 2011, Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis, Carcinogenesis, 32, 477, 10.1093/carcin/bgr009 · DOI
  189. Butti, 2021, Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression, Oncogene, 40, 2002, 10.1038/s41388-021-01663-2 · DOI
  190. Sharon, 2015, Tumor-Derived Osteopontin Reprograms Normal Mammary Fibroblasts to Promote Inflammation and Tumor Growth in Breast Cancer, Cancer Res., 75, 963, 10.1158/0008-5472.CAN-14-1990 · DOI
  191. Weber, 2015, Osteopontin mediates an MZF1–TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer, Oncogene, 34, 4821, 10.1038/onc.2014.410 · DOI
  192. Tokuda, 2021, The interaction between cancer associated fibroblasts and tumor associated macrophages via the osteopontin pathway in the tumor microenvironment of hepatocellular carcinoma, Oncotarget, 12, 333, 10.18632/oncotarget.27881 · DOI
  193. Yuan, 2021, MyD88 in myofibroblasts enhances colitis-associated tumorigenesis via promoting macrophage M2 polarization, Cell Rep., 34, 108724, 10.1016/j.celrep.2021.108724 · DOI
  194. Pestell, 2017, Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth, Oncotarget, 8, 81754, 10.18632/oncotarget.19953 · DOI
  195. Lenos, 2018, Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer, Nat. Cell Biol., 20, 1193, 10.1038/s41556-018-0179-z · DOI
  196. Qin, 2018, Cancer-associated Fibroblast-derived IL-6 Promotes Head and Neck Cancer Progression via the Osteopontin-NF-kappa B Signaling Pathway, Theranostics, 8, 921, 10.7150/thno.22182 · DOI
  197. Jing, 2021, Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis, Oncogene, 40, 2910, 10.1038/s41388-021-01705-9 · DOI
  198. Nazarizadeh, 2021, Evaluation of local and circulating osteopontin in malignant and benign primary bone tumors, J. Bone Oncol., 29, 100377, 10.1016/j.jbo.2021.100377 · DOI
  199. Ji, 2021, SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy, Sci. Rep., 11, 14031, 10.1038/s41598-021-93484-2 · DOI
  200. Moldogazieva, N., Mokhosoev, I., Zavadskiy, S., and Terentiev, A. (2021). Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. Biomedicines, 9. · DOI

200 of 228 shown

Cited by

Sorted by citations

Metadata

Authors
Kariya, Y., & Kariya, Y.
Affiliations
  • Department of Biochemistry, Fukushima Medical University, 1 Hikarigaoka, Fukushima City 960-1295, Fukushima, Japan
  • Medical-Industrial Translational Research Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima City 960-1295, Fukushima, Japan
Venue
International Journal of Translational Medicine
Publisher
MDPI AG
Published
2022-08-19
Volume
2
Issue
3
Pages
419-447
ISSN
2673-8937
DOI
10.3390/ijtm2030033
Cited by
14
References
4
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
Japan Society for Promotion of Science KAKENHI (22K07004)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review